Phase I and early phase II studies on human urinary colony stimulating factor.
スポンサーリンク
概要
- 論文の詳細を見る
This report demonstrates the first trial for the clinical application of human urinary colony stimulating factor (CSFHU) which was highly purified and well characterized in our laboratory. In the Phase I study, 6 healthy volunteers were administered with 2.5×105 to 106 units of CSFHU intravenously. CSFHU did not show any severe side effects, although slight depression of maximum blood pressure was observed in the group injected with 106 units CSFHU and one volunteer who received 5×105 units CSFHU complained sweating and itching during the infusion. In the Phase II study, six cases suffering from lecukocytopenia induced by anticancer drugs or irradiation were treated with 7 day intravenous CSFHU injections. Although recovery of leukocyte number was not observed in the group injected with 7×106 units CSFHU, complete or partial recovery of leukocyte and granulocyte number was observed in the group injected with 1.3 to 1.4×107 units CSFHU, Phase II study in a large scale is under way to evaluate further the effectiveness of CSFHU on leukocytopenic patients.
- 社団法人 日本内科学会の論文
社団法人 日本内科学会 | 論文
- Insulinoma with Six Islet Cell Tumors Associated with Severe Hypoglycemia
- 脳腱黄色腫に微小変化型ネフローゼ症候群を合併した1例
- Brugada Syndrome Case: Difficult Differentiation Between a Concealed Form and Tricyclic Antidepressant-induced Brugada Sign
- Brugada Syndrome Whose ST-segment Changes were Enhanced by Antihistamines and Antiallergenic Drugs
- Edaravone Diminishes Free Radicals from Circulating Neutrophils in Patients with Ischemic Brain Attack